Our website uses cookies so that we can provide you a better online experience and service;
by continuing, you agree to our use of cookies in line with our Privacy Statement
Close
29 May 2014 - 11:41

DuPont Nutrition & Health and AB-Biotics Announce Agreement on Probiotic for Cardiovascular Health

DuPont Nutrition & Health and AB-Biotics have signed a global collaboration and licensing agreement on AB-Life®, a probiotic that is clinically documented to maintain healthy levels of cholesterol in at-risk individuals. Under the agreement, DuPont will have exclusive rights for the production, marketing and sales of AB-Life®; and AB-Biotics will continue to conduct clinical research to further substantiate the proven health benefits of AB-Life®.

AB-Life® is a patented probiotic formulation developed by AB-Biotics, based in Barcelona, Spain.  DuPont is integrating AB-Life® into its documented HOWARU® probiotic range for the dietary supplement and food and beverage industries.  The company expects to launch the product in 4th quarter 2014.

“We are excited to work with AB-Biotics to support probiotics for heart health,” said Fabienne Saadane-Oaks, vice president Health and Protection, DuPont Nutrition & Health.  “Probiotics is a fast-growing segment of our business as people increasingly experience the benefits they can provide. Our HOWARU® formulations have been clinically tested and shown to deliver the digestive and immune support people need, and we are looking forward to adding cardiovascular support to our probiotics portfolio.” 

The new probiotic will complement DuPont’s portfolio for cardiovascular health, which includes Danisco® Pinvita™ phytosterols, Danisco® Evesse™ EPC, a natural apple extract and soy protein to address the needs of a global healthy aging population.

"This agreement marks a significant milestone for AB-Biotics and proves the high value of our patented probiotics and other functional ingredients for the dietary supplement and food and beverage industries,” said Miquel Angel Bonachera and Sergi Audivert, CEOs of AB-Biotics. “Thanks to DuPont we can bring AB-Life® to this market with a top-positioned partner.”

According to the World Health Organization (WHO), cardiovascular diseases are the No. 1 cause of death globally. Forty-three percent of cardiovascular deaths arise from coronary heart disease and 32 percent from strokes; raised cholesterol increases the risks of heart disease and stroke.  Globally, a third of ischaemic heart disease is attributable to high cholesterol.

Industry estimates state that the global retail market for probiotics is estimated at $32 billion and is expected to grow to $45 billion in 2018. More than 90 percent of the total is attributed to food, beverage and dietary supplements. 

The WHO defines probiotics as "live micro-organisms which, when administered in adequate amounts, confer a health benefit on the host."  Probiotics offer unique support for digestive and immune health and other well-being benefits for the dietary supplement, dairy and beverage markets. 

AB-Biotics (ABB:SM) is a biotechnology company focused on research, development, protection and distribution of biotech unique solutions to improve the health and well-being of people. Its areas of activity include the development of pharmacogenetic tests for neuropsychiatry, and probiotics and other functional ingredients for the food and pharmaceutical industries. AB-Biotics is listed on the Spanish Alternative Investment Market (MAB). The company began in 2012 its international expansion and has closed several agreements for marketing their products in America, Europe and Asia. For additional information about AB-Biotics and its pipeline, please visit www.ab-biotics.com.

DuPont Nutrition & Health addresses the world’s challenges in food by offering a wide range of sustainable, bio-based ingredients and advanced molecular diagnostic solutions to provide safer, healthier and more nutritious food.  Through close collaboration with customers, DuPont combines knowledge and experience with a passion for innovation to deliver unparalleled customer value to the marketplace.

DuPont (NYSE: DD) has been bringing world-class science and engineering to the global marketplace in the form of innovative products, materials, and services since 1802.  The company believes that by collaborating with customers, governments, non-governmental organizations, and thought leaders we can help find solutions to such global challenges as providing enough healthy food for people everywhere, decreasing dependence on fossil fuels, and protecting life and the environment.  For additional information about DuPont and its commitment to inclusive innovation, please visit www.dupont.com.

Forward-Looking Statements:  This news release contains forward-looking statements which may be identified by their use of words like "plans," "expects," "will," "believes," "intends," "estimates," "anticipates" or other words of similar meaning.  All statements that address expectations or projections about the future, including statements about the company's growth strategy, product development, regulatory approval, market position, anticipated benefits of acquisitions, outcome of contingencies, such as litigation and environmental matters, expenditures and financial results, are forward-looking statements.  Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized.  Forward-looking statements also involve risks and uncertainties, many of which are beyond the company's control.  Some of the important factors that could cause the company's actual results to differ materially from those projected in any such forward-looking statements are: fluctuations in energy and raw material prices; failure to develop and market new products and optimally manage product life cycles; significant litigation and environmental matters; failure to appropriately manage process safety and product stewardship issues; changes in laws and regulations or political conditions; global economic and capital markets conditions, such as inflation, interest and currency exchange rates; business or supply disruptions; security threats, such as acts of sabotage, terrorism or war, weather events and natural disasters; ability to protect and enforce the company's intellectual property rights; successful integration of acquired businesses and separation of underperforming or non-strategic assets or businesses and successful completion of the proposed spinoff of the Performance Chemicals segment including ability to fully realize the expected benefits of the proposed spinoff .  The company undertakes no duty to update any forward-looking statements as a result of future developments or new information.

The DuPont Oval Logo, DuPont™, The miracles of science™, Danisco® and HOWARU® are registered trademarks or trademarks of DuPont or its affiliates. AB-Life® is a registered trademark of AB-Biotics.

Catherine L. Andriadis
Direct:
+1 302-695-2212
Mobile:
+1 302-383-6081
Location:
Wilmington, USA
Nuria Peláez
AB-Biotics, S.A.
Direct:
+34-654-35-25-41